The Ontario Molecular Pathology Research Network (OMPRN) drives new innovations in cancer research by supporting molecular pathology across the province through a number of competitive grants, which encourage multidisciplinary collaboration and mentorship for trainee and early-career pathologists.
|GRANT||DESCRIPTION||AVAILABLE FUNDS||DUE DATE|
|Cancer Pathology Translational Research Grants Stream 1||Supports several small, one-year, collaborative research projects that bring together a pathologist Principal Investigator (PI) with a trans-disciplinary Co- Investigator and a pathology trainee.||up to $35,000||This call is currently closed|
|Cancer Pathology Translational Research Grants Stream 2||Supports a smaller number of more ambitious, two-year research projects led by an early-career pathologist PI with a transdisciplinary Co- Investigator.||up to $160,000||This call is currently closed|
|Workshop attendance||Funding is available towards registration, accommodation and travel for three Bioinformatics.ca courses.||up to $1,000 towards fees, travel and accommodation||This call is currently closed|
Other Funding Opportunities
This section contains news on other funding opportunities relevant to Ontario pathology researchers.
Stay up to date on the latest events and funding opportunities with the Network! Sign up for the OMPRN newsletter.
|GRANT||DESCRIPTION||AVAILABLE FUNDS||DUE DATE|
|CRS: Scholarships for the Next Generation of Scientists||Scholarships for the Next Generation of Scientists is a Cancer Research Society funding program with the goal of supporting the future generation of Canadian researchers.The award consists of two parts covering a period of three years, with no possibility for renewal.||$180,000 total over 2 years||April 28th 2017|
|CCSRI: Travel Awards||A limited number of Travel Awards to PhD or MD/PhD students, and post-doctoral/medical/clinical fellows are available. The purpose of this program is to defray the travel costs associated with making a scientific presentation as a first author or presenter at a conference, symposium or other appropriate professional meeting.||$2,000 per grant||May 15th 2017|
|NIH: Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)||This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.||Direct costs are limited to $300,000 per year||May 26th and September 26th 2017|
|NIH: Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)||This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.||$400,000 over a 3-year period||May 26th and September 26th 2017|
|NIH: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)||This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.||$400,000 over a 3-year period||May 26th and September 26th 2017|
|CIHR: Project Grant||The Project Grant program is designed to capture ideas with the greatest potential to advance health-related fundamental or applied knowledge, health research, health care, health systems, and/or health outcomes. It supports projects with a specific purpose and a defined endpoint. The best ideas may stem from new, incremental, innovative, and/or high-risk lines of inquiry or knowledge translation approaches.||TBC||May 30, 2017 + other 2017 date TBC|
|NIH: Focused Technology Research and Development (R01)||This initiative will support projects that focus solely on development of technologies with the potential to enable biomedical research. Projects should be justified in terms of potential biomedical impact, but should not include any application to specific biomedical research questions.||Application budgets are not limited but need to reflect the actual needs of the proposed project.||June 5th and October 5th 2017|
|NIH: NCI Small Grants Program for Cancer Research (R03)||This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.||up to $50,000 per year||June 27th, 2017|
|NIH: Exploratory Research for Technology Development (R21)||This initiative will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high risk approaches with potential for significant impact.||$275,000 Direct Costs over the two-year project period||July 16th and October 16th 2017|
|CCSRI: Innovation Grant||The purpose of this funding initiative is to support unique, creative research ideas that will impact cancer. Although this grant program is primarily designed to support the biomedical, translational and clinical research communities, applications from all areas and disciplines of cancer research will be considered eligible for funding and will be evaluated based on a common set of criteria||$100,000 per year and a maximum of $200,000 per grant||August 15th 2017|